PBLS (Parabilis Medicines) NonCurrent Deferred Liabilities: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.43
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines NonCurrent Deferred Liabilities?

Parabilis Medicines PBLS -4.21% 10 NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Parabilis Medicines's non-current deferred liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Parabilis Medicines NonCurrent Deferred Liabilities Related Terms

Parabilis Medicines NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines NonCurrent Deferred Liabilities Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
NonCurrent Deferred Liabilities 0.00 0.00
PBLS
10GF Score
Parabilis Medicines Inc PBLS
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Parabilis Medicines (PBLS) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Parabilis Medicines and its competitors.
Is Parabilis Medicines' NonCurrent Deferred Liabilities too high?
Parabilis Medicines' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' NonCurrent Deferred Liabilities compare to IDYA and ELVN?
Parabilis Medicines' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.43
Price